Specialized IRAK4 Degrader Combinations for High-Risk Patient Populations

The inventive concept discloses novel methods and systems for treating MYD88-mutant B-cell lymphomas in high-risk patient populations, combining IRAK4 degraders with targeted therapies to address specific patient needs.

The original patent disclosed IRAK4 degraders for treating MYD88-mutant B-cell lymphomas, but did not address the unique challenges faced by patients with compromised immune systems, history of bone marrow transplant, high risk of infection, history of cancer treatment, or compromised cardiovascular systems. The new inventive concept solves this problem by providing specialized combinations of IRAK4 degraders with immunoglobulin replacement therapy, cytokine therapy, antimicrobial therapy, chemotherapeutic agents, or cardiovascular protective agents.

The inventive concept comprises administering a therapeutically effective amount of an IRAK4 degrader in combination with one or more targeted therapies, depending on the specific patient population. For patients with compromised immune systems, the IRAK4 degrader is combined with immunoglobulin replacement therapy to enhance the immune response. For patients with a history of bone marrow transplant, the IRAK4 degrader is combined with cytokine therapy to promote hematopoietic recovery. For patients with a high risk of infection, the IRAK4 degrader is combined with antimicrobial therapy to prevent infection. For patients with a history of cancer treatment, the IRAK4 degrader is combined with a chemotherapeutic agent to enhance the antitumor effect. For patients with a compromised cardiovascular system, the IRAK4 degrader is combined with a cardiovascular protective agent to minimize cardiovascular toxicity.

The new inventive concept is novel and non-obvious compared to the original patent, as it provides specific combinations of IRAK4 degraders with targeted therapies to address the unique needs of high-risk patient populations. The inventive step lies in the recognition of the specific challenges faced by these patient populations and the development of tailored treatment regimens to address these challenges.

Alternative embodiments of the inventive concept could include combining IRAK4 degraders with other targeted therapies, such as anti-inflammatory agents or gene therapies. Variations of the inventive concept could include adjusting the dosing regimens or administration schedules of the IRAK4 degrader and targeted therapy to optimize treatment outcomes.

The inventive concept has significant commercial potential in the treatment of MYD88-mutant B-cell lymphomas in high-risk patient populations. The target market includes hospitals, clinics, and research institutions involved in the treatment of B-cell lymphomas, as well as pharmaceutical companies developing IRAK4 degraders and targeted therapies.